Anti-TLR4 antibody treatment has been tested in some inflammatory conditions, such as sepsis and chronic bowel disease, with promising results, showing a decrease in the inflammatory process.[18-19] Hypertension is considered as a chronic inflammatory disease, where elevated pro-inflammatory cytokines and Cox-derived prostanoids, mainly from the Cox-2 isoform, are observed.[20] We hypothesized that the reduction in TLR4 effects, by using neutralizing antibody in vivo, would ameliorate hypertensive low-grade inflammation. Here, PTGS2 is linked to Sepsis.